Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
J. Clin. Invest. Ricardo T. Paniagua, et al. 116:2633 doi:10.1172/JCI28546 [
Go to this article.]
Figure 1Imatinib prevents and treats CIA. (
A–
D) Prevention. DBA/1 mice were administered PBS (
n = 15), 33 mg/kg imatinib (
n = 15), or 100 mg/kg imatinib (
n = 14) orally twice daily starting 1 day prior to induction of CIA. Severity of arthritis was assessed using a visual arthritis scoring system (
A) and caliper measurements of paw thickness (
B). The incidence of arthritis at the termination of the experiment (day 49) (
C) and the mean weights of mice in each group (
D) are presented. The data shown in
A and
B are from a representative of 3 independent experiments, each involving 14–15 mice per experimental arm. (
E and
F) Treatment. Following the development of clinical arthritis (average visual arthritis score of 4), DBA/1 mice with CIA were randomized and treated with PBS (
n = 14), 33 mg/kg imatinib (
n = 14), or 100 mg/kg imatinib (
n = 14) orally twice daily, and disease was monitored using a visual arthritis scoring system (
E) and paw thickness measurements (
F). Values from the presented results are the mean ± SEM for this representative experiment. *
P < 0.05, **
P < 0.01 compared with PBS-treated mice.
